Computational virtual screening and structure-based design of some epidermal growth factor receptor inhibitors

Abstract Background The foremost cause of cancer mortality worldwide was lung cancer. Lung cancer is divided into small cell lung cancer and non-small cell lung cancer (NSCLC). The latter is the main type of lung cancer that account for about 90% of the cancer issues and estimate about 25% of the ca...

Full description

Bibliographic Details
Main Authors: Muhammad Tukur Ibrahim, Adamu Uzairu, Sani Uba, Gideon Adamu Shallangwa
Format: Article
Language:English
Published: SpringerOpen 2020-08-01
Series:Future Journal of Pharmaceutical Sciences
Subjects:
Online Access:http://link.springer.com/article/10.1186/s43094-020-00074-6
_version_ 1818402737619992576
author Muhammad Tukur Ibrahim
Adamu Uzairu
Sani Uba
Gideon Adamu Shallangwa
author_facet Muhammad Tukur Ibrahim
Adamu Uzairu
Sani Uba
Gideon Adamu Shallangwa
author_sort Muhammad Tukur Ibrahim
collection DOAJ
description Abstract Background The foremost cause of cancer mortality worldwide was lung cancer. Lung cancer is divided into small cell lung cancer and non-small cell lung cancer (NSCLC). The latter is the main type of lung cancer that account for about 90% of the cancer issues and estimate about 25% of the cancer mortality each year in the world. Among the types of lung cancer with about 1.5 million patients and less than 20% survival rate is NSCLC. Overexpression of EGFR tyrosine kinase was recognized to be the cause of NSCLC. Therefore, there is a need to develop more EGFR inhibitors due to drug-resistance development by the mutation. Result Computational virtual screening on some epidermal growth factor receptor inhibitors (EGFRL858R/T790M inhibitors or NSCLC therapeutic agents) against their target protein (EGFR tyrosine kinase receptor pdb entry 3IKA) was performed via molecular docking simulation and pharmacokinetics to identify hit compounds with a promising affinity toward their target. The hit compounds discovered were compound 22 with −9.8 kcal/mol, 24 with −9.7 kcal/mol, 17 with −9.7 kcal/mol, and 19 with −9.5 kcal/mol respectively. These lead compounds were further subjected to drug-likeness and ADME prediction and found to be orally bioavailable. Six (6) new EGFRL858R/T790M inhibitors using compound 22 with the highest binding affinity as a template were designed. Conclusion The six newly EGFRL858R/T790M inhibitors were found to have a better binding affinity than the template used in the designing process and AZD9291 (the positive control). None of the designed compounds was found to violate more than the permissible limit set by RO5 thereby predicting their easy transportation, absorption, and diffusion. More so, the designed compounds were found to have good synthetic accessibility which indicates that these designed compounds can be easily synthesized in the laboratory.
first_indexed 2024-12-14T08:13:07Z
format Article
id doaj.art-2f0a2cc6d5864b049c5ec3897ddebc56
institution Directory Open Access Journal
issn 2314-7253
language English
last_indexed 2024-12-14T08:13:07Z
publishDate 2020-08-01
publisher SpringerOpen
record_format Article
series Future Journal of Pharmaceutical Sciences
spelling doaj.art-2f0a2cc6d5864b049c5ec3897ddebc562022-12-21T23:10:01ZengSpringerOpenFuture Journal of Pharmaceutical Sciences2314-72532020-08-016111610.1186/s43094-020-00074-6Computational virtual screening and structure-based design of some epidermal growth factor receptor inhibitorsMuhammad Tukur Ibrahim0Adamu Uzairu1Sani Uba2Gideon Adamu Shallangwa3Department of Chemistry, Faculty of Physical Science, Ahmadu Bello UniversityDepartment of Chemistry, Faculty of Physical Science, Ahmadu Bello UniversityDepartment of Chemistry, Faculty of Physical Science, Ahmadu Bello UniversityDepartment of Chemistry, Faculty of Physical Science, Ahmadu Bello UniversityAbstract Background The foremost cause of cancer mortality worldwide was lung cancer. Lung cancer is divided into small cell lung cancer and non-small cell lung cancer (NSCLC). The latter is the main type of lung cancer that account for about 90% of the cancer issues and estimate about 25% of the cancer mortality each year in the world. Among the types of lung cancer with about 1.5 million patients and less than 20% survival rate is NSCLC. Overexpression of EGFR tyrosine kinase was recognized to be the cause of NSCLC. Therefore, there is a need to develop more EGFR inhibitors due to drug-resistance development by the mutation. Result Computational virtual screening on some epidermal growth factor receptor inhibitors (EGFRL858R/T790M inhibitors or NSCLC therapeutic agents) against their target protein (EGFR tyrosine kinase receptor pdb entry 3IKA) was performed via molecular docking simulation and pharmacokinetics to identify hit compounds with a promising affinity toward their target. The hit compounds discovered were compound 22 with −9.8 kcal/mol, 24 with −9.7 kcal/mol, 17 with −9.7 kcal/mol, and 19 with −9.5 kcal/mol respectively. These lead compounds were further subjected to drug-likeness and ADME prediction and found to be orally bioavailable. Six (6) new EGFRL858R/T790M inhibitors using compound 22 with the highest binding affinity as a template were designed. Conclusion The six newly EGFRL858R/T790M inhibitors were found to have a better binding affinity than the template used in the designing process and AZD9291 (the positive control). None of the designed compounds was found to violate more than the permissible limit set by RO5 thereby predicting their easy transportation, absorption, and diffusion. More so, the designed compounds were found to have good synthetic accessibility which indicates that these designed compounds can be easily synthesized in the laboratory.http://link.springer.com/article/10.1186/s43094-020-00074-6ComputationalDockingEGFRL858R/T790MInhibitorsADMEDrug-likeness
spellingShingle Muhammad Tukur Ibrahim
Adamu Uzairu
Sani Uba
Gideon Adamu Shallangwa
Computational virtual screening and structure-based design of some epidermal growth factor receptor inhibitors
Future Journal of Pharmaceutical Sciences
Computational
Docking
EGFRL858R/T790M
Inhibitors
ADME
Drug-likeness
title Computational virtual screening and structure-based design of some epidermal growth factor receptor inhibitors
title_full Computational virtual screening and structure-based design of some epidermal growth factor receptor inhibitors
title_fullStr Computational virtual screening and structure-based design of some epidermal growth factor receptor inhibitors
title_full_unstemmed Computational virtual screening and structure-based design of some epidermal growth factor receptor inhibitors
title_short Computational virtual screening and structure-based design of some epidermal growth factor receptor inhibitors
title_sort computational virtual screening and structure based design of some epidermal growth factor receptor inhibitors
topic Computational
Docking
EGFRL858R/T790M
Inhibitors
ADME
Drug-likeness
url http://link.springer.com/article/10.1186/s43094-020-00074-6
work_keys_str_mv AT muhammadtukuribrahim computationalvirtualscreeningandstructurebaseddesignofsomeepidermalgrowthfactorreceptorinhibitors
AT adamuuzairu computationalvirtualscreeningandstructurebaseddesignofsomeepidermalgrowthfactorreceptorinhibitors
AT saniuba computationalvirtualscreeningandstructurebaseddesignofsomeepidermalgrowthfactorreceptorinhibitors
AT gideonadamushallangwa computationalvirtualscreeningandstructurebaseddesignofsomeepidermalgrowthfactorreceptorinhibitors